Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001931901 | SCV002123755 | pathogenic | Methylmalonic aciduria, cblA type | 2021-08-07 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg214Glufs*4) in the MMAA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MMAA are known to be pathogenic (PMID: 15523652, 15781192). For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with MMAA-related conditions. This variant is not present in population databases (ExAC no frequency). |
Prevention |
RCV003401788 | SCV004104237 | likely pathogenic | MMAA-related disorder | 2023-02-27 | criteria provided, single submitter | clinical testing | The MMAA c.639delT variant is predicted to result in a frameshift and premature protein termination (p.Arg214Glufs*4). To our knowledge, this variant has not been reported in the literature. This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in MMAA are expected to be pathogenic (see, for example, Martínez et al. 2005. PubMed ID: 15781192; Lerner-Ellis et al. 2004. PubMed ID: 15523652). Taken together, this variant is interpreted as likely pathogenic. |